127 completed, 19 terminated, 15 unknown, 9 recruiting. 185 Phase 2, 25 Phase 1, 9 Phase 3.
Follow Chronic Obstructive Pulmonary Disease: new trials by email Literature Review of Chronic Obstructive Pulmonary Disease trials Research Report on Chronic Obstructive Pulmonary Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD Inhaled Nitric Oxide, Placebo - Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Not yet recruiting | University of Alberta | 80 | 2026-12-01 | 2026-07-08 |
| A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping® Lingchang®) for the Treatment of Chronic Obstructive Pulmonary Disease TQC3927 inhalation aerosol, Glyceryl bromide/formoterol inhalation aerosol - Chronic Obstructive Pulmonary Disease | Phase 2 | Suspended | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 90 | 2026-12-01 | 2026-09-03 |
| A Study to Evaluate the Efficacy and Safety of RSS0343 Tablets in Patients With Chronic Obstructive Pulmonary Disease RSS0343 tablets, RSS0343 tablets Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Recruiting | Reistone Biopharma Company Limited | 300 | 2026-03-10 | 2026-06-05 |
| A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease CM326 dose 1, CM326 dose 2, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 318 | 2025-12-18 | 2026-02-18 |
| A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease Ensifentrine 3 mg, Glycopyrrolate 42.5 mcg, Ensifentrine 1.5 mg - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 33 | 2025-10-06 | 2026-01-08 |
| Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212) Ensifentrine 3 mg, Glycopyrrolate 21.25 mcg, Glycopyrrolate 42.5 mcg - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 497 | 2025-07-31 | 2026-09-11 |
| A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD Verekitug, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Active not recruiting | Upstream Bio Inc. | 666 | 2025-07-02 | 2026-07-20 |
| A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary Disease CM512, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Not yet recruiting | Keymed Biosciences Co.Ltd | 204 | 2025-06-20 | 2025-05-20 |
| Sedation vs No Sedation in Mechanically Ventilated COPD Patients Midalozam - Chronic Obstructive Pulmonary Disease, Respiratory Failure | Phase 2 | Completed | Al-Azhar University | 100 | 2025-04-14 | 2026-06-02 |
| A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease TQC2938 injection, TQC2938 injection Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 256 | 2025-03-17 | 2026-04-07 |
| A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease TQC2731 injection, TQC2731 Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Active not recruiting | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 258 | 2024-12-31 | 2025-12-12 |
| A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease CM310, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 / Phase 3 | Not yet recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 884 | 2024-09-13 | 2024-08-14 |
| A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD Glycopyrrolate (85 μg), Glycopyrrolate (42.5 μg), Glycopyrrolate (14 μg) - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 46 | 2024-08-16 | 2026-02-09 |
| A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD Dexpramipexole Dihydrochloride - Chronic Obstructive Pulmonary Disease | Phase 2 | Active not recruiting | Areteia Therapeutics | 30 | 2024-07-09 | 2025-05-14 |
| Treatment of Chronic Obstructive Pulmonary Disease by Infusion of Allogenic Mesenchymal Stem Cells UMC119-06-05 - Chronic Obstructive Pulmonary Disease | Phase 2 | Recruiting | Meribank Biotech Co., Ltd. | 90 | 2024-06-11 | 2024-07-08 |
| Oral Iloprost for the Prevention of Lung Cancer In Former Smokers Biospecimen Collection, Bronchial Brush Biopsy, Bronchoscopy - Bronchial Epithelial Dysplasia, Chronic Obstructive Pulmonary Disease | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-06-01 | 2024-05-17 | |
| Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH Tadalafil, Placebo - Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension | Phase 2 | Recruiting | VA Office of Research and Development | 126 | 2024-04-01 | 2026-05-15 |
| The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome) bi-level positive pressure non invasive ventilation, Oxygen gas - Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease | Phase 2 | Recruiting | University of California, San Diego | 240 | 2024-02-13 | 2026-06-03 |
| Feasibility of Semaglutide in Advanced Lung Disease Semaglutide Pen Injector - Obesity, Interstitial Lung Disease | Phase 1 / Phase 2 | Recruiting | University of Pennsylvania | 8 | 2024-01-29 | 2026-04-21 |
| A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease HRG2005 inhalation, Placebo to match HRG2005 inhalation, Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation - Chronic Obstructive Pulmonary Disease | Phase 2 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 82 | 2024-01-15 | 2025-12-22 |
Showing 20 of 185. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (185) · Emphysema (17) · Bronchitis, Chronic (11) · Hypertension, Pulmonary (9) · Dyspnea (8) · Asthma (6) · Lung Diseases (6) · Bronchiolitis Obliterans Syndrome (4) · Lung Diseases, Obstructive (4) · Motor Activity (4) · Diabetes Mellitus (3) · Heart Failure (3) · Respiration Disorders (3) · Respiratory Insufficiency (3) · Disease (2)
Chronic Disease (185) · Disease Attributes (185) · Pathologic Processes (185) · Pathological Conditions, Signs and Symptoms (185) · Respiratory Tract Diseases (185) · Lung Diseases, Obstructive (181) · Lung Diseases (179) · Bronchial Diseases (21) · Respiration Disorders (16) · Bronchitis (14) · Cardiovascular Diseases (14) · Infections (14) · Respiratory Tract Infections (14) · Signs and Symptoms (14) · Immune System Diseases (13)
Formoterol Fumarate (14) · Tiotropium Bromide (10) · Glycopyrrolate (8) · Fluticasone (4) · Salmeterol Xinafoate (4) · Budesonide (3) · Cholecalciferol (3) · Iloprost (3) · Inhalation (3) · Ipratropium (3) · Sodium Chloride (3) · ensifentrine (3) · indacaterol (3) · 4-((5-chloro-2-pyridinyl)oxy)-1-((((4S)-4-methyl-2,5-dioxo-4-imidazolidinyl)methyl)sulfonyl)-piperidine (2) · Aspirin (2)
AstraZeneca (13) · Pearl Therapeutics, Inc. (11) · Chiesi Farmaceutici S.p.A. (10) · Novartis (6) · Novartis Pharmaceuticals (5) · Dey (4) · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (4) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (3) · Sunovion Respiratory Development Inc. (3) · University of Alabama at Birmingham (3) · University of Alberta (3) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (2) · Genentech, Inc. (2) · Merck Sharp & Dohme LLC (2) · National Heart, Lung, and Blood Institute (NHLBI) (2)
United States (79) · United Kingdom (38) · Germany (23) · Canada (14) · China (14) · Poland (14) · Australia (10) · Belgium (10) · Netherlands (10) · Bulgaria (9) · South Korea (9) · Czechia (8) · France (8) · Hungary (8) · Spain (8)
Colin Reisner, M.D. (6) · Ahmet Tutuncu, MD, PhD (2) · Andrew Lockton, MD (2) · Colin Reisner, MD (2) · Dave Singh (2) · Dave Singh, MD (2) · Esther Garcia, MD (2) · Gerard J Criner, MD (2) · Margaret K Covey, PhD, RN (2) · Yun M Shim, MD (2)
PMID 20920189, PMID 22465313, PMID 24432712, PMID 25287629, PMID 29975735, PMID 12543832, PMID 15319045, PMID 16611654, PMID 16796497, PMID 17296644, PMID 18655841, PMID 18972276, PMID 19017883, PMID 19179484, PMID 19436683, PMID 19460848, PMID 20008582, PMID 20090057, PMID 20154234, PMID 20541381, PMID 21184620, PMID 21514398, PMID 21524765, PMID 21689019, PMID 22235841, PMID 22280813, PMID 22458939, PMID 22793945, PMID 22893340, PMID 23098686, PMID 23217058, PMID 23257347, PMID 23539534, PMID 23681559, PMID 24484754, PMID 24717626, PMID 24958605, PMID 25027304, PMID 25038985, PMID 25060541, PMID 25146558, PMID 25243340, PMID 25336939, PMID 25383540, PMID 25476069, PMID 25526796, PMID 25762226, PMID 26050967, PMID 26318254, PMID 26341216
2015 (5), 2009 (3), 2017 (2), 2018 (2), R33AT009991 (2), 2005 (1), 2008 (1), 2016 (1), 2019 (1), 2025 (1), I01CX002543 (1), P30CA016056 (1), P30CA060553 (1), P30DK072482 (1), P50AT000437 (1)